Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Immunotherapies in 2023

The rise of precision cellular therapies

Nature Reviews Rheumatology volume 20, pages 69–70 (2024)Cite this article

Subjects

Advances in gene, protein and cellular engineering provide unprecedented opportunities to redirect immune cells to treat autoimmunity. In 2023, novel cellular and precision immunotherapies showed remarkable promise in the treatment of rheumatic diseases.

Key advances

  • B cell-targeted CAR T cell therapies can achieve prolonged clinical remission in various autoimmune diseases2,5.

  • Precision cellular therapies hold promise for selective, antigen-specific elimination of autoreactive B cells6.

  • TCR β-chain variable (TRBV)-targeted antibodies also show potential in T cell-mediated rheumatic diseases10.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Emerging immunotherapies for autoimmune and rheumatic diseases.

References

  1. Mueller, F. et al. CD19-targeted CAR-T cells in refractory systemic autoimmune diseases: a monocentric experience from the first fifteen patients. Blood 142, 220–220 (2023).

    Article  Google Scholar 

  2. Qin, C. et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct. Target. Ther. 8, 5 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229–1238 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Britanova, O. V. et al. Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis. Nat. Med. 29, 2731–2736 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pecher, A.-C. et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. J. Am. Med. Assoc. 329, 2154–2162 (2023).

    Article  CAS  Google Scholar 

  6. Cortés Hernández, J. et al. An open-label, multicenter, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: preliminary results [abstract]. Arthritis Rheumatol. 75, suppl 9 (2023).

  7. Feng, J., Hu, Y., Chang, A. H. & Huang, H. CD19/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus - safety and preliminary efficacy data from a phase i clinical study. Blood 142, 4835–4835 (2023).

    Article  Google Scholar 

  8. Yuan, Y. et al. Novel BCMA-CD19 compound CAR-T (cCAR) targets B cells and plasma cells achieving immune reset and eliminates all autoantibodies in systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients resulting in long-term, medication-free remission [abstract]. Arthritis Rheumatol. 75, suppl 9 (2023).

  9. Mog, B. et al. Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells [abstract]. Arthritis Rheumatol. 74, suppl 9 (2022).

  10. Paul, S. et al. TCR β chain–directed bispecific antibodies for the treatment of T cell cancers. Sci. Transl. Med. 13, eabd3595 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Maximilian F. Konig

  2. Ludwig Center for Cancer Genetics and Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Maximilian F. Konig

Authors
  1. Maximilian F. Konig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maximilian F. Konig.

Ethics declarations

Competing interests

M.F.K. is a consultant to Argenx, Atara Biotherapeutics, Revel Pharmaceuticals, Sana Biotechnology and Sanofi. M.F.K. declares that he and The Johns Hopkins University have filed patent applications related to chimeric autoantigen-T cell receptor-T cell therapies and TCR region-targeting approaches.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Konig, M.F. The rise of precision cellular therapies. Nat Rev Rheumatol 20, 69–70 (2024). https://doi.org/10.1038/s41584-023-01073-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-023-01073-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing